Product Benefits

• Comprehensive Airway Management: Combines Salmeterol (a LABA) which relaxes and widens the air passages for 12 hours of easier breathing, with Fluticasone (an ICS) which reduces the chronic inflammation and swelling in the lungs.

• Effective Exacerbation Reduction: The combination therapy is highly effective in decreasing the frequency and severity of asthma and COPD flare-ups, which can lead to emergency visits or hospitalization.

• Symptom Improvement: Provides significant long-term improvement in key symptoms of chronic respiratory disease, including a reduction in wheezing, shortness of breath, and coughing.

• Improved Quality of Life: Consistent, regular use of the maintenance therapy helps stabilize lung function and enables patients to participate more actively in daily life with fewer breathing restrictions.

• High-Dose Anti-Inflammatory Component: The $250\text{mcg}$ dose of Fluticasone Propionate makes this strength particularly suitable for patients with moderate to severe persistent asthma or COPD requiring a higher level of corticosteroid to control inflammation.